Bariederm Cream in Chronic Contact Dermatitis

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02026700

Enrollment

Registered

2014-01-03

Start date

2014-02-28

Completion date

2015-03-31

Last updated

2014-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contact Dermatitis

Brief summary

We intend to evaluate the efficiency and tolerability of a barrier cream (bariederm) in protecting hands of individuals with hand dermatitis, either due to allergy or irritation. We believe that the use of the cream would benefit with the skin.

Detailed description

The aim of the study is the evaluation of the effectiveness, tolerance and cosmetic acceptability of Bariéderm cream among patients presenting with chronic allergic or irritant contact dermatitis of the hands. We shall enrol adults presenting with CONTACT DERMATITIS EXCLUDING FLARE-UPS of the hands: whether allergic or irritant, able to understand the protocol and agrees to sign the information and informed consent form. Bariéderm cream will be applied minimum twice daily over 21 days. Response will be evaluated by self and physician filled questionnaires. effectiveness, tolerance and cosmetic acceptability will be evaluated by a scale of 1-10, 1 meaning not at all and 10 meaning very much. Statistics will be performed by SPSS software with suitable statistical tests. In case of an adverse event caused by the product, patch-test with ingredients of Bariéderm cream will be performed.

Interventions

DEVICEbariederm cream

patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* patients with dermatitis of the hands

Exclusion criteria

* pregnant ladies, * known allergy to ingredients -

Design outcomes

Primary

Measure	Time frame	Description
self evaluation of effectiveness and tolerance in a 1-10 scale	21 days	effectiveness tolerance and acceptability in adults with hand dermatitis, evaluated by a self reported and a physician reported questionaires, using a 1-10 scale for evaluation.

Countries

Israel

Contacts

Primary Contactliran horev, md

rlirano@hadassah.org.il00972508573992

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026